/** Title: NGL Fine-Chem Q4 FY26: Volume-led recovery, capex execution, and the next regulatory milestones */

NGL Fine-Chem Q4 and FY26: Volume-led recovery, margin repair, and a delayed but progressing expansion

NGL Fine-Chem ended FY26 on a stronger footing, with Q4 delivering another quarter of volume-led growth. Revenue from operations rose to INR 149.23 crore in Q4 FY26, up 57% year on year and 17% sequentially. EBITDA expanded sharply versus last year to INR 21.41 crore, translating to a 14.35% margin, while PAT improved to INR 13.49 crore.

The full-year picture reinforces that the company has exited a difficult phase. FY26 revenue from operations increased 36% year on year to INR 500.95 crore. EBITDA more than doubled to INR 72.69 crore and PAT climbed to INR 48.13 crore. Management described FY26 as a clear recovery year after three challenging years, with the last three quarters showing sustained improvement.

The quarter was not a straight-line margin story. Management pointed to higher freight and raw material costs driven by geopolitical volatility, and noted that part of the business operates under fixed-price contracts, delaying immediate pass-through. In addition, forex movement led to mark-to-market provisions, along with mark-to-market on investments, which depressed margins sequentially. While the company did not quantify the forex impact, management stated it was a meaningful contributor to the quarter’s elevated other expenses.

Business mix: Animal API remains dominant, with broad-based geographic demand

NGL’s revenue mix remains heavily weighted towards Animal APIs. In Q4 FY26, Animal API contributed 95% of revenue, while Human API accounted for 2% and Intermediates and Formulations were 1% each. On geographies, Asia contributed 43% in Q4 FY26, India 23%, Europe 9%, and the rest of world 26%.

The company also disclosed concentration metrics that suggest a diversified customer base for an API exporter. In Q4 FY26, the top 10 customers accounted for 29% of sales and the top 10 products contributed 66% of sales. Management highlighted this diversification while discussing sustained demand traction across the portfolio and markets.

Capacity expansion: Phase I helping volumes; Phase II delayed to early Q2 FY27

Capacity execution remains central to NGL’s near-term narrative. Management stated that Phase I of its expansion programme is already contributing meaningfully and that the higher volumes in Q4 were comfortably absorbed within expanded capacity. In the concall, management clarified that Phase I included not only a small-volume clean room for validation batches but also an intermediate plant. This additional intermediate capacity, combined with increased outsourcing of intermediates, supported the recent volume rise.

The more material milestone is Phase II of the greenfield expansion at Tarapur. The company disclosed an estimated capex of INR 210 crore for the Tarapur project, to be funded through debt and internal accruals, and stated it had invested INR 182.75 crore up to Q4 FY26. During the quarter, shortages of gas and labour slowed construction, pushing commissioning from Q1 FY27 to early Q2 FY27. Despite the delay, management reiterated that commercial production is expected to start from H2 FY27.

The balance sheet reflects the capex cycle. Total assets increased to INR 545.50 crore in FY26 from INR 433.39 crore in FY25. Long-term borrowings increased to INR 56.40 crore from INR 25.34 crore, while short-term borrowings rose to INR 52.02 crore from INR 48.00 crore. Cash and bank balances were modest at INR 5.11 crore in FY26.

Cash flows indicate that capex continues to dominate cash deployment. FY26 operating cash flow was INR 43.32 crore, investing cash flow was negative INR 70.59 crore, and net cash flow was positive INR 2.27 crore.

Margin outlook: partial pass-through achieved; target band reiterated

Management’s margin commentary focused on restoring profitability after cost inflation. It stated that partial price pass-through has been secured with customers in the first quarter of FY27, which should help restore margins. The company maintained an EBITDA margin intent of 15% to 18% and said it is close to that level. Management also suggested that margin improvement should become more visible from Q2, since the impact of price increases began flowing mainly from the current month, while Q1 may still see minor fluctuations.

Competitive intensity remains a constraint. Management stated that competition from Chinese and Indian players continues. It also explained that the industry experienced oversupply and significant price erosion in 2024 and 2025, and it does not expect a quick return to earlier peak margins in the near term.

Regulated markets: progress in Europe; US timelines dependent on customers and regulator

Beyond volume recovery and capacity, investors are focused on the timeline for regulated market scaling. On Europe, management stated it currently has 3 CEPs approved, 3 CEPs under review, and 2 CEPs being prepared for submission in the current quarter. It also referenced having 5 DMS registered and 4 DMS under review. Management indicated Europe approvals can take around 18 months and expects some approvals in the second half of calendar 2026. It also stated that Europe sales are expected to start in the current year.

The US is structurally less predictable. Management said it has already filed 5 VMS and plans to file another 6 in the current year. It explained that USFDA inspection is triggered only after customers file to add NGL as an additional supplier, and then the inspection depends on USFDA scheduling. As a result, the timing could be within the current year or the next year. Management indicated that the bulk of regulated market revenues is expected only from FY28, with Europe contribution starting earlier.

Takeaways

NGL Fine-Chem’s FY26 performance shows a clear volume-led recovery, backed by improved capacity utilisation and broader demand across products and geographies. The key near-term execution item is Phase II commissioning, now expected in early Q2 FY27, with commercial production targeted for H2 FY27.

On margins, the company has reiterated its 15% to 18% EBITDA intent and stated that partial price pass-through has already begun, with improvement expected from Q2. The next leg of the story will be defined by consistency in the INR 150 crore-plus quarterly revenue run-rate, disciplined completion of the capex cycle, and tangible progress in Europe and US regulatory milestones that can shift the company’s medium-term growth mix.